NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

被引:501
作者
Wu, DC
Teismann, P
Tieu, K
Vila, M
Jackson-Lewis, V
Ischiropoulos, H
Przedborski, S [1 ]
机构
[1] Columbia Univ, Dept Neurol, New York, NY 10032 USA
[2] Columbia Univ, Dept Pathol, New York, NY 10032 USA
[3] Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA
[4] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA
[5] Childrens Hosp Philadelphia, Dept Pediat, Stokes Res Inst, Philadelphia, PA USA
关键词
D O I
10.1073/pnas.0937239100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Parkinson's disease (PD) is a neuroclegenerative disorder of uncertain pathogenesis characterized by a loss of substantia nigra pars compacta (SNpc) clopaminergic (DA) neurons, and can be modeled by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Both inflammatory processes and oxidative stress may contribute to MPTP- and PD-related neurodegeneration. However, whether inflammation may cause oxidative damage in MPTP and PD is unknown. Here we show that NADPH-oxidase, the main reactive oxygen species (ROS)-producing enzyme during inflammation, is up-regulated in SNpc of human PD and MPTP mice. These changes coincide with the local production of ROS, microglial activation, and DA neuronal loss seen after MPTP injections. Mutant mice defective in NADPH-oxidase exhibit less SNpc DA neuronal loss and protein oxidation than their WT littermates after MPTP injections. We show that extracellular ROS are a main determinant in inflammation-mediated DA neurotoxicity in the MPTP model of PD. This study supports a critical role for NADPH-oxidase in the pathogenesis of PD and suggests that targeting this enzyme or enhancing extracellular antioxidants may provide novel therapies for PD.
引用
收藏
页码:6145 / 6150
页数:6
相关论文
共 29 条
  • [1] Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
    Ara, J
    Przedborski, S
    Naini, AB
    Jackson-Lewis, V
    Trifiletti, RR
    Horwitz, J
    Ischiropoulos, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (13) : 7659 - 7663
  • [2] NADPH oxidase: An update
    Babior, BM
    [J]. BLOOD, 1999, 93 (05) : 1464 - 1476
  • [3] Bindokas VP, 1996, J NEUROSCI, V16, P1324
  • [4] Chen H, 2002, MOVEMENT DISORD, V17, pS143
  • [5] Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo
    Dehmer, T
    Lindenau, J
    Haid, S
    Dichgans, J
    Schulz, JB
    [J]. JOURNAL OF NEUROCHEMISTRY, 2000, 74 (05) : 2213 - 2216
  • [6] Fahn S, 2000, MERRITTS NEUROLOGY, P679
  • [7] FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61
  • [8] Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease
    Gao, HM
    Jiang, J
    Wilson, B
    Zhang, W
    Hong, JS
    Liu, B
    [J]. JOURNAL OF NEUROCHEMISTRY, 2002, 81 (06) : 1285 - 1297
  • [9] Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions
    Giasson, BI
    Duda, JE
    Murray, IVJ
    Chen, QP
    Souza, JM
    Hurtig, HI
    Ischiropoulos, H
    Trojanowski, JQ
    Lee, VMY
    [J]. SCIENCE, 2000, 290 (5493) : 985 - 989
  • [10] GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691